Purified (+)-cis-THC Enantiomer for Epilepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The therapeutic potential of (+)-cis-tetrahydrocannabinol (THC) has not been established, and existing methods do not effectively utilize this enantiomer for medicinal purposes due to its low natural occurrence and lack of understanding of its pharmacological activity compared to its (−)-trans isomer.
Innovation Solution
The development of highly purified (+)-cis-THC, either from plant extracts or synthetic production, for use as a medicament, with specific dosing ranges and combination with pharmaceutically acceptable excipients, demonstrating its efficacy in animal models of disease, particularly in epilepsy and seizure treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If highly purified (+)-cis-THC is produced through synthetic means or extraction, then the purity and therapeutic efficacy are improved, but the manufacturing complexity and cost increase
Solution Approach 1:
The patent extracts (+)-cis-THC from cannabis plant material through purification processes, separating the desired enantiomer from other cannabinoids and plant compounds. This extraction approach obtains highly purified (+)-cis-THC while managing manufacturing complexity through established extraction and purification techniques.
Solution Approach 2:
The patent employs synthetic methods that control stereochemical parameters to produce enantiomerically pure (+)-cis-THC. By manipulating synthesis conditions and catalysts, the manufacturing process achieves high purity of the specific enantiomer while managing process complexity through controlled chemical transformations.
2Reliability
If (+)-cis-THC is used as a medicament, then therapeutic efficacy is improved, but the lack of established pharmacological data creates uncertainty
Solution Approach 1:
The patent conducts preliminary pharmacological studies and animal model testing to establish the safety and efficacy profile of (+)-cis-THC before clinical use. This preliminary action generates essential pharmacological data, reducing uncertainty and informing dosing recommendations for future therapeutic applications.
3Quantity of substance
If natural cannabis plant strains are used to obtain (+)-cis-THC, then the compound is obtained naturally, but the concentration is too low for practical use
Solution Approach 1:
The patent uses extraction and purification processes to concentrate (+)-cis-THC from low-concentration plant material. By selectively extracting and purifying the target compound, the method overcomes the low natural concentration issue while maintaining a practical starting material source.
Solution Approach 2:
The patent transitions from relying on natural plant concentrations to using synthetic production methods that can achieve high concentrations of (+)-cis-THC. This parameter change in the production approach directly addresses the low concentration limitation of natural sources.
Data Source
AI summary
The present invention relates to a tetrahydrocannabinol (THC) type cannabinoid compound for use as a medicament. The THC-type cannabinoid is an enantiomer of the (−)-trans- tetrahydrocannabinol which is a naturally occurring cannabinoid that can be found in cannabis plant strains which have been bred to yield THC as the dominant cannabinoid. The particular enantiomer (+)-cis tetrahydrocannabinol has been found to have properties which are different from the naturally occurring (−)-trans-THC. The cannabinoid (+)-cis-THC has been found to occur in low concentrations in particular cannabis plant strains which have been bred to produce cannabidiol (CBD) as the dominant cannabinoid. Furthermore, the cannabinoid can be produced by synthetic means.